Evidence map›Paper›PMID 24475288›Full record

ArticlePloS one2014

Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells.

Paolo B Abada, Stephen B Howell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Role of OCT4 in cancer stem-like cells and chemotherapy resistance.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.Journal of cancer research and clinical oncology · 2016
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paolo B AbadaDepartment of Medicine and the Moores UCSD Cancer Center, University of California San Diego, La Jolla, California, United States of America.
Stephen B HowellDepartment of Medicine and the Moores UCSD Cancer Center, University of California San Diego, La Jolla, California, United States of America.
University of California, San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Control of the cellular pharmacology of the platinum-containing drugs by CTR1R01CA152185 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOWELL, STEPHEN B · 2010 to 2014
$1.5M
NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA152185NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at the site of the primary tumor suggesting that cisplatin may trigger differentiation in some tumors. Using the human embryonal carcinoma cell line NTera2/D1, we confirmed that exposure to the differentiating agent retinoic acid produced a reduction in pluripotency markers NANOG and POU5F1 (Oct3/4) and an acute concentration-dependent increase in resistance to both cisplatin and paclitaxel that reached as high as 18-fold for cisplatin and 61-fold for paclitaxel within four days. A two day exposure to cisplatin also produced a concentration-dependent decrease in the expression of the NANOG and POU5F1 and increased expression of three markers whose levels increase with differentiation including Nestin, SCG10 and Fibronectin. In parallel, exposure to cisplatin induced up to 6.2-fold resistance to itself and 104-fold resistance to paclitaxel. Paclitaxel did not induce differentiation or resistance to either itself or cisplatin. Neither retinoic acid nor cisplatin induced resistance in cervical or prostate cancer cell lines or other germ cell tumor lines in which they failed to alter the expression of NANOG and POU5F1. Forced expression of NANOG prevented the induction of resistance to cisplatin by retinoic acid. We conclude that cisplatin can acutely induce resistance to itself and paclitaxel by triggering a differentiation response in pluripotent germ cell tumor cells.

Indexed as

Blotting, WesternCell DifferentiationCell Line, TumorCell SurvivalCisplatinDrug Resistance, NeoplasmFibronectinsHomeodomain ProteinsHumansMaleMembrane ProteinsNanog Homeobox ProteinNeoplasms, Germ Cell and EmbryonalNestinOctamer Transcription Factor-3Real-Time Polymerase Chain ReactionCisplatinFibronectinsHomeodomain ProteinsMembrane ProteinsNanog Homeobox ProteinNANOG protein, humanNestinOctamer Transcription Factor-3POU5F1 protein, humanStathminSTMN2 protein, humanTretinoin

Identifiers

PMID24475288
PMCPMC3903721
OpenAlexW1972652789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.